Who Pays My Doctor?

Healthcare provider profile · identity verified

James Avery Rush, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · AMARILLO, TX · NPI 1992975841

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show James Avery Rush, M.D. received $266,660.87 in general payments during 2025 across 551 reported records.

Neurocrine BioSciences, Inc. accounted for 37.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 17 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Rexulti, Spravato.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Auvelity by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Spravato by this doctor in 2024.

Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 586 records involving 456 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Spravato by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$266,660.87

551 reported records · 12 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Neurocrine BioSciences, Inc. Unresolved — no canonical attribution shown $99,131.6337.2%1532025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $56,033.7421.0%982025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $55,433.2620.8%802025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $39,090.4814.7%602025
Janssen Pharmaceuticals, Inc Unresolved — no canonical attribution shown $15,197.575.7%642025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $474.240.2%242025
Teva Pharmaceuticals USA, Inc. Unresolved — no canonical attribution shown $393.030.1%332025
Lundbeck LLC Unresolved — no canonical attribution shown $252.650.1%122025
Janssen Scientific Affairs, LLC Unresolved — no canonical attribution shown $200.000.1%12025
Alkermes, Inc. Unresolved — no canonical attribution shown $166.230.1%112025
ABBVIE INC. Unresolved — no canonical attribution shown $145.430.1%72025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $142.610.1%82025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$217,791.0083
Travel and Lodging$27,210.89147
Consulting Fee$11,500.004
Food and Beverage$10,158.98317

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
INGREZZA
Normalized: ingrezza		 Drug Neurocrine BioSciences, Inc. $99,131.63 153 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $55,391.82 79 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc. $43,502.97 92 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $39,090.48 60 2025
Source payment records
INVEGA SUSTENNA
Normalized: invega sustenna		 Drug Janssen Pharmaceuticals, Inc $14,347.74 33 2025
Source payment records
INVEGA TRINZA
Normalized: invega trinza		 Drug Janssen Pharmaceuticals, Inc $14,297.73 31 2025
Source payment records
ABILIFY ASIMTUFII
Normalized: abilify asimtufii		 Drug Otsuka America Pharmaceutical, Inc. $12,783.42 18 2025
Source payment records
ABILIFY MAINTENA
Normalized: abilify maintena		 Drug Otsuka America Pharmaceutical, Inc. $12,783.42 18 2025
Source payment records
SPRAVATO
Normalized: spravato		 Drug Janssen Pharmaceuticals, Inc, Janssen Scientific Affairs, LLC $924.96 29 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $474.24 24 2025
Source payment records
AUSTEDO XR
Normalized: austedo xr		 Drug Teva Pharmaceuticals USA, Inc. $211.06 21 2025
Source payment records
UZEDY
Normalized: uzedy		 Drug Teva Pharmaceuticals USA, Inc. $181.97 12 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $166.23 11 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $166.23 11 2025
Source payment records
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $145.43 7 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $142.61 8 2025
Source payment records
INVEGA
Normalized: invega		 Drug Janssen Pharmaceuticals, Inc $12.42 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
Auvelity
auvelity		 2025 Auvelity 2024 21
Beneficiary count suppressed		 exact normalized Medicare Part D
REXULTI
rexulti		 2025 Rexulti 2024 14
Beneficiary count suppressed		 exact normalized Medicare Part D
SPRAVATO
spravato		 2025 Spravato 2024 309 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
Axsome Therapeutics, Inc.
Exact reporting entity; no affiliate inference		 2025 Auvelity
open payments reported associated product		 CMS Open Payments — General Payments
116023 supporting records · 35298 recipient NPIs · example record 1235293064 		Auvelity · 2024
Exact normalized brand match · 1 Part D row		 21 suppressed by CMS
Janssen Pharmaceuticals, Inc
Exact reporting entity; no affiliate inference		 2025 SPRAVATO
open payments reported associated product		 CMS Open Payments — General Payments
43813 supporting records · 17025 recipient NPIs · example record 1174223254 		Spravato · 2024
Exact normalized brand match · 1 Part D row		 309 13
Janssen Scientific Affairs, LLC
Exact reporting entity; no affiliate inference		 2025 SPRAVATO
open payments reported associated product		 CMS Open Payments — General Payments
586 supporting records · 456 recipient NPIs · example record 1174147619 		Spravato · 2024
Exact normalized brand match · 1 Part D row		 309 13
Lundbeck LLC
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
71829 supporting records · 25812 recipient NPIs · example record 1251759986 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 14 suppressed by CMS
Otsuka America Pharmaceutical, Inc.
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
160756 supporting records · 46288 recipient NPIs · example record 1227267708 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 14 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
SpravatoEsketamine Hcl30913
Duloxetine HclDuloxetine Hcl7813
ClonazepamClonazepam6115
Trazodone HclTrazodone Hcl39suppressed
AlprazolamAlprazolam33suppressed
Bupropion XlBupropion Hcl33suppressed
Venlafaxine Hcl ErVenlafaxine Hcl33suppressed
Quetiapine FumarateQuetiapine Fumarate29suppressed
Methylphenidate HclMethylphenidate Hcl25suppressed
AuvelityDextromethorphan Hbr/Bupropion21suppressed
Buspirone HclBuspirone Hcl21suppressed
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine21suppressed
Donepezil HclDonepezil Hcl17suppressed
Escitalopram OxalateEscitalopram Oxalate17suppressed
Citalopram HbrCitalopram Hydrobromide16suppressed
AripiprazoleAripiprazole15suppressed
Fluoxetine HclFluoxetine Hcl15suppressed
MirtazapineMirtazapine15suppressed
RexultiBrexpiprazole14suppressed
Zolpidem TartrateZolpidem Tartrate13suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $266,660.87 · 551 records Neurocrine BioSciences, Inc. ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, FANAPT, INGREZZA, INVEGA, INVEGA SUSTENNA, INVEGA TRINZA, LYBALVI, REXULTI, SPRAVATO, UZEDY, VRAYLAR 5 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error